Precerebral Occlusion without Infarction with MCC DRG Reimbursement

DRG 067 addresses hospitalizations for precerebral arterial occlusion without infarction when a Major Complication or Comorbidity is present; it covers transient ischemic events or symptomatic vessel occlusion absent completed stroke. Correct assignment to this Diagnosis-Related Group influences Medicare inpatient reimbursement by reflecting the higher expected resource use when a Major Complication or Comorbidity exists.

DRG 067 Overview

DRG 067 covers hospital admissions for precerebral arterial occlusion without established cerebral infarction when a Major Complication or Comorbidity is present. This category includes patients with symptomatic carotid or vertebral artery narrowing or occlusion causing transient ischemic symptoms but without completed stroke, and the presence of a Major Complication or Comorbidity increases resource intensity. It matters for Medicare inpatient reimbursement because classification into this Diagnosis-Related Group affects payment relative to less or more severe cerebrovascular Diagnosis-Related Groups. Accurate documentation of the precipitating vascular condition and the Major Complication or Comorbidity is essential for proper payment assignment.

Acute endovascular and medical management trials focused on preventing progression to cerebral infarction: these studies evaluate timing and efficacy of urgent revascularization procedures (such as carotid or vertebral artery interventions) and adjunctive antithrombotic regimens in patients who present with symptomatic precerebral occlusion but have no established brain infarction on imaging. The patient population includes hospitalized adults with high-grade extracranial or proximal intracranial arterial stenosis/occlusion, often with transient ischemic symptoms, and research questions center on which immediate interventions reduce early stroke conversion and inpatient morbidity. Findings are highly relevant to providers for optimizing in-hospital care pathways and to payers because effective acute strategies can shorten length of stay, reduce need for higher-cost complications, and affect payer-covered procedural and ICU resource utilization.
Comparative effectiveness studies of secondary prevention strategies during the inpatient stay: these trials compare different combinations of antiplatelet, anticoagulant, and risk-factor management protocols initiated in hospital for patients with precerebral occlusion without infarction, including subgroups with atrial fibrillation or carotid disease. The target population is medically heterogeneous hospitalized patients at high short-term risk for stroke who may benefit from tailored secondary prevention; research objectives include balancing recurrent event reduction against bleeding and other adverse events. Results inform clinicians on best practice bundles to implement before discharge and inform payers about cost-effectiveness and readmission risk associated with differing inpatient medication and monitoring strategies.
Post-discharge outcomes and care-transition studies assessing readmission, functional status, and long-term vascular events: these observational cohorts and interventional trials evaluate discharge planning, outpatient follow-up timing, rehabilitation referral, and adherence programs for patients who had precerebral occlusion without infarction during an index admission. The population includes survivors discharged without infarction but with high vascular risk, with research questions about which transitional care models reduce 30- and 90-day readmissions, new infarcts, or disability. These studies are important to hospitals and payers because improved transitions can lower readmission penalties, reduce downstream high-cost events, and guide reimbursement for outpatient care coordination services.

Acute endovascular and medical management trials focused on preventing progression to cerebral infarction: these studies evaluate timing and efficacy of urgent revascularization procedures (such as carotid or vertebral artery interventions) and adjunctive antithrombotic regimens in patients who present with symptomatic precerebral occlusion but have no established brain infarction on imaging. The patient population includes hospitalized adults with high-grade extracranial or proximal intracranial arterial stenosis/occlusion, often with transient ischemic symptoms, and research questions center on which immediate interventions reduce early stroke conversion and inpatient morbidity. Findings are highly relevant to providers for optimizing in-hospital care pathways and to payers because effective acute strategies can shorten length of stay, reduce need for higher-cost complications, and affect payer-covered procedural and ICU resource utilization.
Comparative effectiveness studies of secondary prevention strategies during the inpatient stay: these trials compare different combinations of antiplatelet, anticoagulant, and risk-factor management protocols initiated in hospital for patients with precerebral occlusion without infarction, including subgroups with atrial fibrillation or carotid disease. The target population is medically heterogeneous hospitalized patients at high short-term risk for stroke who may benefit from tailored secondary prevention; research objectives include balancing recurrent event reduction against bleeding and other adverse events. Results inform clinicians on best practice bundles to implement before discharge and inform payers about cost-effectiveness and readmission risk associated with differing inpatient medication and monitoring strategies.
Post-discharge outcomes and care-transition studies assessing readmission, functional status, and long-term vascular events: these observational cohorts and interventional trials evaluate discharge planning, outpatient follow-up timing, rehabilitation referral, and adherence programs for patients who had precerebral occlusion without infarction during an index admission. The population includes survivors discharged without infarction but with high vascular risk, with research questions about which transitional care models reduce 30- and 90-day readmissions, new infarcts, or disability. These studies are important to hospitals and payers because improved transitions can lower readmission penalties, reduce downstream high-cost events, and guide reimbursement for outpatient care coordination services.

OpenPayer

Summary & Overview

Precerebral Occlusion without Infarction with MCC: Inpatient Reimbursement Overview

DRG 067 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes